StockNote
DHT
Ha Tay Pharmaceutical Joint Stock Company (DHT), formerly known as Ha Tay Pharmaceutical Enterprise, was established in 1965. In 2001, the company switched to a joint stock company. The company specializes in manufacturing and trading pharmaceuticals, medicinal materials, cosmetics, nutritious foods and medical equipment. The company is one of the few units that has invested in facilities that meet GMP-WHO quality standards, including laboratories that meet GLP standards, warehouse systems according to GSP standards. DHT owns the first two factories in the North that meet GMP standards, with a production line of tablets - non-beta-lactam with a capacity of 3,520,000,000 tablets/year, a workshop producing antibiotics with a production capacity of 495,000,000 tablets/year. On December 3, 2008, DHT officially traded on the Hanoi Stock Exchange (HNX).
DHT currently has a market capitalization of roughly VND 5.425 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 131x is 152% above its own 8-year average (51,9x), suggesting the stock is trading richer than its historical norm. P/B stands at 5x, 31% above its multi-year average of 3,8x. Return on equity (ROE) is at 3,8%, down from 4,9% the year before. Its debt-to-equity ratio of 0,3x is low, reflecting a conservative capital structure. In 2025, revenue grew 15% year-on-year while after-tax profit fell 21%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.